Véronique Debien, Medical Oncologist at Institute Bergonié, shared a post on LinkedIn:
“First time at the AACR-NCI-EORTC Target25 Meeting in Boston
Presenting our poster on ctDNA-detected ERBB2 amplifications across patients with advanced/metastatic solid tumors at Institut Bergonié.
Take-home: when ERBB2 CNV is detected in ctDNA, the result often arrives earlier than tissue, and it enables access to anti-HER2 therapies for patients who would otherwise have had no such option, directly influencing treatment and early-phase trial referrals.
This meeting is a perfect place to learn what the next generation of drugs in trials will look like, several of them already open for enrolment in our Early Phase unit, and to exchange directly with those who design and run these studies, from the clinic side and from pharma.”
More posts featuring Véronique Debien on OncoDaily.